Company: SYRA
Filing Date: 2025-09-19
Form Type: DEF 14A
Source: 0001493152-25-014246
Chunk: 36

Company: Syra Health Corp
Filing Date: 2025-09-19
Form: DEF 14A
Chunk 36
---
 5% of any class of our voting securities, including any of their immediate family members and any entity owned or controlled by such persons.

| 26 |

Under the policy, if a transaction has been identified as a related person transaction, including any transaction that was not a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our management must present information regarding the related person transaction to our audit committee, or, if audit committee approval would be inappropriate, to another independent body of our board of directors, for review, consideration and approval or ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant stockholder to enable us to identify any existing or potential related-person transactions and to effectuate the terms of the policy. In addition, under our code of business conduct and ethics, our employees and directors will have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest. In considering related person transactions, our audit committee, or other independent body of our board of directors, will take into account the relevant available facts and circumstances including, but not limited to:

| ● | the                                                                                                                           
 risks, costs and benefits to us;                                                                                              |
| ● | the                                                                                                                           
 impact on a director’s independence in the event that the related person is a director, immediate family member of a director 
 or an entity with which a director is affiliated;                                                                             |
| ● | the                                                                                                                           
 availability of other sources for comparable services or products; and                                                        |
| ● | the                                                                                                                           
 terms available to or from, as the case may be, unrelated third parties or to or from employees generally.                    |

The policy requires that, in determining whether to approve, ratify or reject a related person transaction, our audit committee, or other independent body of our board of directors, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our stockholders, as our audit committee, or other independent body